These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30556550)

  • 1. Genetically-engineered protein prodrug-like nanoconjugates for tumor-targeting biomimetic delivery via a SHEATH strategy.
    Chang Y; Yao S; Chen Y; Huang J; Wu A; Zhang M; Xu F; Li F; Huang Y
    Nanoscale; 2019 Jan; 11(2):611-621. PubMed ID: 30556550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tandem fusion of albumin-binding domains promoted soluble expression and stability of recombinant trichosanthin in vitro and in vivo.
    Ren Z; Zhao J; Cao X; Wang F
    Protein Expr Purif; 2022 Dec; 200():106147. PubMed ID: 35917982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intein-mediated site-specific synthesis of tumor-targeting protein delivery system: Turning PEG dilemma into prodrug-like feature.
    Chen Y; Zhang M; Jin H; Tang Y; Wang H; Xu Q; Li Y; Li F; Huang Y
    Biomaterials; 2017 Feb; 116():57-68. PubMed ID: 27914267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glioma Dual-Targeting Nanohybrid Protein Toxin Constructed by Intein-Mediated Site-Specific Ligation for Multistage Booster Delivery.
    Chen Y; Zhang M; Jin H; Li D; Xu F; Wu A; Wang J; Huang Y
    Theranostics; 2017; 7(14):3489-3503. PubMed ID: 28912890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precisely albumin-hitchhiking tumor cell-activated reduction/oxidation-responsive docetaxel prodrugs for the hyperselective treatment of breast cancer.
    Wei W; Luo C; Yang J; Sun B; Zhao D; Liu Y; Wang Y; Yang W; Kan Q; Sun J; He Z
    J Control Release; 2018 Sep; 285():187-199. PubMed ID: 30017721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL.
    Li R; Yang H; Jia D; Nie Q; Cai H; Fan Q; Wan L; Li L; Lu X
    J Control Release; 2016 Apr; 228():96-106. PubMed ID: 26951928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood-Brain-Barrier-Penetrating Albumin Nanoparticles for Biomimetic Drug Delivery via Albumin-Binding Protein Pathways for Antiglioma Therapy.
    Lin T; Zhao P; Jiang Y; Tang Y; Jin H; Pan Z; He H; Yang VC; Huang Y
    ACS Nano; 2016 Nov; 10(11):9999-10012. PubMed ID: 27934069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-Delivery of Trichosanthin and Albendazole by Nano-Self-Assembly for Overcoming Tumor Multidrug-Resistance and Metastasis.
    Tang Y; Liang J; Wu A; Chen Y; Zhao P; Lin T; Zhang M; Xu Q; Wang J; Huang Y
    ACS Appl Mater Interfaces; 2017 Aug; 9(32):26648-26664. PubMed ID: 28741923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
    Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
    Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multifunctional Tumor-Targeting Cathepsin B-Sensitive Gemcitabine Prodrug Covalently Targets Albumin in Situ and Improves Cancer Therapy.
    Zhang H; Sun Z; Wang K; Li N; Chen H; Tan X; Li L; He Z; Sun J
    Bioconjug Chem; 2018 Jun; 29(6):1852-1858. PubMed ID: 29775284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide-nanoparticle ligation mediated by cutinase fusion for the development of cancer cell-targeted nanoconjugates.
    Galbiati E; Cassani M; Verderio P; Martegani E; Colombo M; Tortora P; Mazzucchelli S; Prosperi D
    Bioconjug Chem; 2015 Apr; 26(4):680-9. PubMed ID: 25741889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roles of Albumin-Binding Proteins in Cancer Progression and Biomimetic Targeted Drug Delivery.
    Zhao P; Wang Y; Wu A; Rao Y; Huang Y
    Chembiochem; 2018 Sep; 19(17):1796-1805. PubMed ID: 29920893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel antitumor prodrug platform designed to be cleaved by the endoprotease legumain.
    Stern L; Perry R; Ofek P; Many A; Shabat D; Satchi-Fainaro R
    Bioconjug Chem; 2009 Mar; 20(3):500-10. PubMed ID: 19196156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prodrug-Like, PEGylated Protein Toxin Trichosanthin for Reversal of Chemoresistance.
    Chen Y; Zhang M; Jin H; Tang Y; Wu A; Xu Q; Huang Y
    Mol Pharm; 2017 May; 14(5):1429-1438. PubMed ID: 28195491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles.
    Kratz F
    J Control Release; 2008 Dec; 132(3):171-83. PubMed ID: 18582981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Redox-sensitive polyglutamic acid-platinum(IV) prodrug grafted nanoconjugates for efficient delivery of cisplatin into breast tumor.
    Wang R; He D; Wang H; Wang J; Yu Y; Chen Q; Sun C; Shen Y; Tu J; Xiong Y
    Nanomedicine; 2020 Oct; 29():102252. PubMed ID: 32615336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antitumor effect of recombinant immunotoxin EGF-TCS in nude mice bearing human hepatocellular carcinoma].
    Yang HW; Yang HW; Li YM
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Oct; 27(10):1535-6. PubMed ID: 17959515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing the circulating half-life and the antitumor effects of a tumor-selective cytotoxic peptide by exploiting endogenous serum albumin as a drug carrier.
    Su T; Yang H; Fan Q; Jia D; Tao Z; Wan L; Lu X
    Int J Pharm; 2016 Feb; 499(1-2):195-204. PubMed ID: 26752086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel trichosanthin fusion protein with increased cytotoxicity to tumor cells.
    Lin B; Yang XZ; Cao XW; Zhang TZ; Wang FJ; Zhao J
    Biotechnol Lett; 2017 Jan; 39(1):71-78. PubMed ID: 27714558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
    Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
    J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.